Iambic Therapeutics — Third Quarter 2026 Earnings Summary
Financial Performance:
- Collaboration revenue was $11.4 million for the third quarter of 2026, compared to $4.7 million for the same period in 2025.
- Year-to-date (through Q3 2026) collaboration revenue was approximately $24 million, compared to $8.6 million for the same period in 2025.
- Billings from collaborations were approximately $100 million year-to-date 2026, compared to $19.0 million for the same period in 2025.
- Research and development expenses were $34.1 million for the third quarter of 2026, compared to $23.1 million for the third quarter of 2025.
- General and administrative expenses were $7.4 million for the third quarter of 2026, compared to $4.3 million for the third quarter of 2025.
- Total operating expenses were $41.5 million for the third quarter of 2026, compared to $27.3 million for the third quarter of 2025.
- Net loss was $38.5 million for the third quarter of 2026, compared to $21.5 million for the third quarter of 2025.
- Net loss for the third quarter of 2026 included a $10.4 million non-cash charge related to the change in fair value of convertible notes.
- Costs related to compute were less than $10 million for the year-to-date period through Q3 2026.
- Cash and cash equivalents were $252.0 million as of September 30, 2026.
- Pro-forma cash and cash equivalents as of September 30, 2026, were approximately $455 million, including $156 million in IPO net proceeds and $47 million in AbbVie upfront payments received in October 2026.
- Deferred revenue increased to $96.1 million ($45.8 million current, $50.3 million non-current) as of September 30, 2026, from $20.4 million ($11.3 million current, $9.1 million non-current) as of December 31, 2025.
- Accounts receivable and unbilled receivables were $55.8 million as of September 30, 2026, compared to $1.3 million as of December 31, 2025.
- Convertible notes were $76.9 million as of September 30, 2026, compared to $0 as of December 31, 2025.
Business Segments and Product Lines:
- Launched Enchant v3, a 41-billion-parameter transformer model for drug discovery and development.
- IAM1363 (HER2) Phase 1/2 data presented at ESMO 2026 showed a 36% best overall response rate (systemic) and 41% best overall response rate (intracranial) in heavily pretreated patients.
- 15 participants in the IAM1363 study remained on treatment for at least 6 months.
- IAM1363 registrational trial is planned for 2027, subject to regulatory approval.
- Submitted IND and received a Safe-to-Proceed Letter from the FDA for the IAM217 (KIF18A) Phase 1/2 trial.
- IND submission for IAM-C1 (CDK2/4) is on track for Q4 2026.
- IAM217 preclinical data showed approximately 90% regression in an intracranial tumor model.
- IAM-C1 is designed to avoid CDK1, CDK6, CDK7, and CDK9.
- Advancing multiple wholly owned discovery programs against hard-to-drug targets in oncology, metabolic, and endocrine diseases.
Market and Competitive Landscape:
- Signed AI discovery collaborations with Bayer and AbbVie, bringing the total number of partnerships signed since 2024 to eight.
- Achieved a program milestone in the Takeda collaboration in Q3 2026, triggering a $1.0 million payment nine months after the partnership announcement.
- Continuing work with Lundbeck, Revolution Medicines, Jazz Pharmaceuticals, NVIDIA, and Lambda.
- Management states that collaborations with AbbVie, Bayer, and Takeda reflect growing industry demand for AI-driven drug discovery.
Management Commentary and Tone:
- CEO Tom Miller, PhD, stated the company's mission is to make better technology for better medicines and that recent months demonstrated this across every part of the business.
- Management highlighted the intracranial activity and tolerability of IAM1363 and the launch of Enchant v3 as significant advances.
- Management noted that partnership payments have been an efficient way to fund the company while serving the industry.
- Management expressed confidence that the IPO provides resources to advance the pipeline through major inflection points and scale the platform.
Other Key Points:
- Closed IPO in October 2026, selling 10,781,250 shares at $16.00 per share, including the full exercise of the underwriters' option.
- Gross proceeds from the IPO were $172.5 million, with net proceeds of approximately $156.0 million.
- Common stock began trading on the Nasdaq Global Select Market under the ticker "IAM" on October 15, 2026.
- Samit Hirawat, MD, joined the Board of Directors in August 2026.
- William (Bill) Rastetter, PhD, was named Chairperson of the Board.
- Sunny Chang, JD, was promoted to General Counsel.
- Moving headquarters to a 121,000-square-foot facility in the Torrey Pines area of San Diego beginning November 2026.
- Participating in the Jefferies Global Healthcare Conference (November 16-19, 2026), Citi Global Healthcare Conference (December 1-3, 2026), and J.P. Morgan Healthcare Conference (January 11-14, 2027).
- Company
- IAMBIC THERAPEUTICS INC
- Sector
- Healthcare
- Industry
- Biotechnology